阿尔茨海默病中的手性:系统性审查
Yilamujiang Abuduaini1, Wei Chen2, Xiang-Zhen Kong3
1Department of Psychology and Behavioral Sciences, Zhejiang University, Hangzhou, China.
Brain research
|July 25, 2024
概括
手的偏好不是诊断阿尔茨海默病 (AD) 或其亚型的可靠指标. 目前的研究,包括对1万多名患者的元分析,显示了不一致的发现,表明手性缺乏对AD的诊断实用性.
科学领域:
- 神经科学是一个神经科学.
- 神经学 神经学
- 心理学 心理学 心理学
背景情况:
- 传统上,手性作为大脑横向化的代理.
- 阿尔茨海默病 (AD) 涉及神经退行,影响侧面认知功能,如视觉空间和语言技能.
- 关于阿尔茨海默病与手性之间的联系的先前研究已经产生了不一致的结果.
研究的目的:
- 为研究阿尔茨海默病 (AD) 和其亚型 (早期和晚期发病) 的手偏好提供最新的研究综述.
- 评估手性作为AD生物标志物的诊断实用性.
主要方法:
- 系统的文献综述和现有关于AD手性研究的综合研究.
- 来自1万多名阿尔茨海默病患者的数据的元分析.
主要成果:
- 这些发现表明,研究手性与阿尔茨海默病之间的关系的研究存在显著的不一致性.
- 分析结果证实,手性对阿尔茨海默病及其亚型缺乏诊断效用.
- 手的偏好不是阿尔茨海默病的可靠生物标志物.
结论:
- 手性不是阿尔茨海默病或其亚型的有用诊断生物标志物.
- 未来的研究应该利用先进的神经成像来探索AD中的大脑不对称性.
- 需要进一步研究AD中大脑侧向化的情况.
相关概念视频
Alzheimer's Disease: Overview
456
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
456
Lateralization
319
Brain lateralization refers to the division of mental processes and functions between the two hemispheres of the brain, a phenomenon that optimizes neural efficiency and underpins complex abilities in humans. This specialization allows each hemisphere to perform tasks where it has a comparative advantage, facilitating more refined cognitive capabilities across different domains.
319
Alzheimer's Disease: Treatment
172
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
172


